Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 0.72 |
| ▸ | RAB9A | P51151 | 14/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6381967 | 0.98 | NPC1 (0.70) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL4155826 | 0.86 | NPC1 (0.53) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| Hydrochloric Acid SCHEMBL6384354 | 0.84 | NPC1 (0.51) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL192332 | 0.84 | NPC1 (1.00) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL5341764 | 0.83 | DYRK1A (0.52) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| Hydrochloric Acid SCHEMBL4255724 | 0.82 | NPC1 (0.96) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL3930292 | 0.82 | NPC1 (0.72) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL10347638 | 0.82 | NPC1 (0.96) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL1819290 | 0.82 | NPC1 (0.72) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL5591590 | 0.82 | NPC1 (0.62) | NPC1RAB9AKDM4EHKDC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041782-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Shanghai Ruotuo Biosciences (CN) | 2026-02-12 | — | — | US | claimed |
| WO-2025040743-A1 | CONJUGATED TLR7 AND RIG-I AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2025-02-27 | — | — | WO | claimed |
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2024037503-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO., LTD. (CN) | 2024-02-22 | — | — | WO | claimed |
| CN-110869360-B | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| EP-4255903-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Eubulus Biotherapeutics Inc. (CN) | 2023-10-11 | — | — | EP | claimed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | claimed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | claimed |
| WO-2022117064-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2022-06-09 | — | — | WO | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041782-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGRT, FCGR2A, NR3C1 | NPC1 365/4885RAB9A 680/4885KDM4E 4116/4885 |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | NPC1 2178/4885RAB9A 3687/4885KDM4E 1703/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | NPC1 2178/4885RAB9A 3687/4885KDM4E 1703/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | NPC1 2178/4885RAB9A 3687/4885KDM4E 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.